Verve Therapeutics Past Earnings Performance
Past criteria checks 0/6
Verve Therapeutics's earnings have been declining at an average annual rate of -29.9%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 90.1% per year.
Key information
-29.9%
Earnings growth rate
57.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 90.1% |
| Return on equity | -38.7% |
| Net Margin | -807.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Dec 08
Verve Therapeutics: An In Vivo Gene Editing 'Moon Shot' For Your Portfolio
Aug 30Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Revenue & Expenses Breakdown
How Verve Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 24 | -197 | 55 | 0 |
| 30 Jun 24 | 21 | -193 | 53 | 0 |
| 31 Mar 24 | 16 | -197 | 52 | 0 |
| 31 Dec 23 | 12 | -200 | 50 | 0 |
| 30 Sep 23 | 8 | -193 | 49 | 0 |
| 30 Jun 23 | 5 | -192 | 47 | 0 |
| 31 Mar 23 | 3 | -179 | 43 | 0 |
| 31 Dec 22 | 2 | -157 | 38 | 0 |
| 30 Sep 22 | 1 | -148 | 33 | 0 |
| 30 Jun 22 | 0 | -125 | 29 | -25 |
| 31 Mar 22 | 0 | -137 | 24 | -11 |
| 31 Dec 21 | 0 | -120 | 19 | 0 |
| 30 Sep 21 | 0 | -113 | 14 | 16 |
| 30 Jun 21 | 0 | -99 | 10 | 48 |
| 31 Mar 21 | 0 | -53 | 7 | 40 |
| 31 Dec 20 | 0 | -46 | 5 | 0 |
Quality Earnings: VERV is currently unprofitable.
Growing Profit Margin: VERV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VERV is unprofitable, and losses have increased over the past 5 years at a rate of 29.9% per year.
Accelerating Growth: Unable to compare VERV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VERV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: VERV has a negative Return on Equity (-38.74%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 01:54 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Verve Therapeutics, Inc. is covered by 20 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Clarence Powell | BMO Capital Markets Equity Research |
| Whitney Ijem | Canaccord Genuity |